E3 Ligase Screening and Profiling Services
As a LifeSensors customer you
will be consulting with a member of our team to discuss the scope of work
relating to your project. Projects may include but are not limited to any or
all of the above services (i.e. services described on the DUB screening
page). Some typical examples are listed
DUB chain linkage selectivity: estimated project time, 2-3 weeks
In vitro assay development: estimated project time, 2-4 weeks
IC50 determination: estimated project time, 50 compounds per DUB per week
High-throughput screen of 500,000 compounds: estimated project time, 3-6 weeks
The DUB screening process is a customized job. Approximate time frames will vary based on customer projects. LifeSensors will work with individual customers to put together a timeline for their individual project process.
LifeSensors will identify the best screening platform for your project, predict and overcome potential pitfalls, and provide you with rapid results. Our team’s combined experience in the ubiquitin field will enable us to understand your project at a deep level, accelerate your data collection, and aid you in interpreting the results. We will accelerate and enhance your drug discovery efforts, allowing you identify the most promising hit compounds and advance them based on potency and selectivity to cellular and in vivo studies.
LifeSensors has developed quantitative plate-based assays to determine the most optimal E2 for your E3. The E2 can determine the ubiquitin chain-linkage type produced, and the ability of your E3 to ubiquitylate substrates. Thus, E2 selection is closely intertwined with the physiological consequences of E3 ligase activity.
Ub Chain Identification
Different types of ubiquitination linkage patterns can have different functional consequences for the substrate. Knowing the type of chain and branching can give you insights into the signaling mechanism and role of your E3 or substrate of interest. We use a variety of technologies for this work, including but not limited to the following:
- Mutant Ub (K6, K11, K27, K29, K33, K48, K63, and Met1) gel/WB
- Ubiquitin linkage K-GG LC-MS/MS
E3 Screening and Compound Profiling
Targeting E3 ligases can be difficult because of the many components in the ubiquitin cascade, but LifeSensors can help you identify potent and selective compounds. Using our in-house library or your own library, we can identify and develop inhibitors and activators of your E3 of interest. In fact, with our E3 TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) assay you can simultaneously screen multiple E3s for activation. Development includes establishing selectivity, specificity, and binding. Following the in vitro work, we can help you determine in vivo target engagement and biomarkers with our TUBE technology. Contact us now!
Inhibition Frequency Distribution: Typical frequency distribution of compound inhibition levels from a screening campaign and subsequent primary confirmation. As expected, the library screen produces a normal distribution of inhibition percentages, while compounds selected for follow-up exhibit significant, reproducible inhibition of E3 ligase activity.
E3 hit selection by single point inhibition. Selectivity profile of E3 ligase inhibitors for E3 ligases X and Y at a single concentration, measured by TR-FRET assay. Compounds with high percent inhibition for E3 Y only are considered to be selective, while those with percent inhibitions greater than 30% for E3 X are considered nonselective.
E3 ligase selectivity profiling: Selectivity profile of a potent E3 ligase inhibitor (Compound Y) measured by TR-FRET assay. As demonstrated by the IC50 curves, the compound is several orders of magnitude more potent against E3s A and B than E3s C and D.